We can’t show the full text here under this license. Use the link below to read it at the source.
Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
Comparing two diabetes drug types for treating fatty liver disease
AI simplified
Abstract
GLP-1RA was significantly superior in reducing liver fat content by 2.42 units compared to TZD in a meta-analysis of 2,237 patients.
- GLP-1RA also led to a greater reduction in body mass index by 1.60 units and waist circumference by 4.89 units compared to TZD.
- In liver biopsy evaluations, GLP-1RA showed a tendency to outperform TZD, though the difference was not statistically significant.
- Both GLP-1RA and TZD were analyzed for their effects on (NAFLD) and (NASH).
- Sensitivity analysis confirmed the robustness of the findings regarding GLP-1RA's advantages.
AI simplified
Key numbers
-2.42
Reduction in Liver Fat Content
Mean difference in liver fat content measured by H-MRS.
-1.60
Decrease in Body Mass Index (BMI)
Mean difference in BMI between GLP-1RA and TZD.
-4.89
Decrease in Waist Circumference
Mean difference in waist circumference between GLP-1RA and TZD.